Hamad S. AlAkrash , Hisham M. Ghabbani , Faisal A. AlSaleh , Rashad M. Nassar , Almaha A. AlHumaidan , Abdullateef M. AlHasan , Abdullah M. AlMosa , Abdulaziz A. AlBluwi , Hossam S. Eltholoth , Nagoud M. Ali , Ahmed Y. AlZahrani
{"title":"Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma: Rare subset case report","authors":"Hamad S. AlAkrash , Hisham M. Ghabbani , Faisal A. AlSaleh , Rashad M. Nassar , Almaha A. AlHumaidan , Abdullateef M. AlHasan , Abdullah M. AlMosa , Abdulaziz A. AlBluwi , Hossam S. Eltholoth , Nagoud M. Ali , Ahmed Y. AlZahrani","doi":"10.1016/j.eucr.2024.102798","DOIUrl":null,"url":null,"abstract":"<div><p>Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC) is a rare subtype of renal cell carcinoma characterized by genetic rearrangements involving the ALK gene. Managing ALK-RCC is challenging due to its rarity and limited treatment options. Targeted therapies directed at the ALK gene have shown promise.</p><p>ALK-RCC is a rare subtype of renal cell carcinoma with unique clinical and pathological features. ALK inhibitors may hold promise as a targeted therapy for ALK-RCC. Further research is needed to understand the behavior of ALK-RCC and develop effective treatment strategies.</p></div>","PeriodicalId":38188,"journal":{"name":"Urology Case Reports","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214442024001529/pdfft?md5=21b01006552300408ae55c795acb1dfb&pid=1-s2.0-S2214442024001529-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214442024001529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC) is a rare subtype of renal cell carcinoma characterized by genetic rearrangements involving the ALK gene. Managing ALK-RCC is challenging due to its rarity and limited treatment options. Targeted therapies directed at the ALK gene have shown promise.
ALK-RCC is a rare subtype of renal cell carcinoma with unique clinical and pathological features. ALK inhibitors may hold promise as a targeted therapy for ALK-RCC. Further research is needed to understand the behavior of ALK-RCC and develop effective treatment strategies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
